Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Loxo Oncology, Inc.
| Metric | Loxo Oncology, Inc. Healthcare |
|---|---|
| Quality Score | 58 / 100 |
| Revenue (latest) | $0 |
| Net income (latest) | −$25M |
| Operating margin | — |
| Net margin | — |
| Return on equity | −6.5% |
| Return on assets | −3.1% |
| Return on capital (ROCE) | −27.1% |
| Debt / equity | 1.07× |
| Revenue growth (YoY) | — |
| Altman Z″ (distress) | 3.16 |
| Accruals / assets | −16.9% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.